Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Multiple Myeloma 5Breast Neoplasms 4Vomiting 3Neoplasms 3Lymphoma, Non-Hodgkin 3Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Nausea 2Hodgkin Disease 2Hematologic Neoplasms 2Endometrial Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Pathologic Complete Response 1Paraproteinemias 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1NSCLC 1Mucositis 1Mastocytosis, Systemic 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Diphenhydramine × Clear all
NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Not yet recruiting
430 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡